Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Orforglipron improves cardiovascular risk markers in diabetes and obesity.
Última actualización 6 de julio de 2026
Key finding
Decreases in SBP were observed with orforglipron by -7.3 to -9.4 mmHg.
Orforglipron treatment led to significant reductions in cardiovascular risk markers among participants with type 2 diabetes and obesity.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Extended (5–20+ y)
Risk of bias
High Risk
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
Orforglipron treatment led to significant reductions in cardiovascular risk markers among participants with type 2 diabetes and obesity.
Clinical relevance
The findings highlight the potential of orforglipron as a therapeutic option for managing cardiovascular risk in patients with type 2 diabetes and obesity. Given the high prevalence of cardiovascular disease in this population, effective interventions are crucial for improving health outcomes and reducing healthcare costs.
Keep in mind
Unclear effectiveness for some outcomes. Limited generalizability due to specific population characteristics. Potential unmeasured confounders affecting results.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Sean W, Julio R, Manige K, et al. Orforglipron treatment was associated with beneficial changes in cardiovascular risk markers in participants with type 2 diabetes and obesity. Cardiovascular Diabetology. 2025;24:240. doi:10.1186/s12933-025-02781-x
Efectos Principales
Systolic blood pressure decreased by -8.4 mmHg (p=0.001).
Diastolic blood pressure decreased by -1.5 mmHg (p=0.05).
LDL cholesterol decreased by -14.3 mg/dL (p=0.001).
Triglycerides decreased by -16.4 mg/dL (p=0.001).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Orforglipron and Apolipoprotein B change, Apolipoprotein C3 change, C-reactive protein, and 5 more.
This study contributes evidence to
Primary intervention
Orforglipron
Primary outcomes
- Apolipoprotein B change
- Apolipoprotein C3 change
- C-reactive protein
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
8
Evidence pairs
8
Relationships
1
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 63
1
Related topics
8
Evidence pairs
58
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 8 evidence relationships
- Includes primary outcome data
- Linked to 1 direct semantic evidence topic
Topic contributions
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Tema de evidencia
Inflammatory and Vascular Markers
matched_outcome
Core evidence
Study findings
The primary outcomes reported in this study.
Apolipoprotein C3 change
Orforglipron → Apolipoprotein C3 change
Orforglipron → Apolipoprotein C3 change
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerDiastolic blood pressure
Orforglipron → Diastolic blood pressure
Orforglipron → Diastolic blood pressure
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- Orforglipron reduced systolic blood pressure by 8.4 mmHg.
- LDL cholesterol levels decreased by 14.3 mg/dL.
- Significant reductions in inflammatory markers were observed.
A quién se aplica
- Adults with type 2 diabetes.
- Individuals with obesity.
Tener en Cuenta
- Results may not apply to populations outside the study.
- Further research is needed to confirm long-term effects.
- Effectiveness was unclear for some cardiovascular risk markers.
Entre Líneas
- Unclear effectiveness for some outcomes.
- Limited generalizability due to specific population characteristics.
- Potential unmeasured confounders affecting results.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Orforglipron and Apolipoprotein B change, Orforglipron and Apolipoprotein C3 change.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Orforglipron → Apolipoprotein B change
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
View evidenceMedications
Orforglipron → Apolipoprotein C3 change
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
View evidenceMedications
Orforglipron → Blood Pressure
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
Apolipoprotein B change Evidence Hub
All studies measuring Apolipoprotein B change
1 studies
outcome_hubMeasures Apolipoprotein B change as a key outcome.
Apolipoprotein C3 change Evidence Hub
All studies measuring Apolipoprotein C3 change
1 studies
outcome_hubMeasures Apolipoprotein C3 change as a key outcome.
Blood Pressure Evidence Hub
All studies measuring Blood Pressure
1 studies
outcome_hubMeasures Blood Pressure as a key outcome.
Orforglipron Evidence Hub
All studies on Orforglipron
1 studies
intervention_hubContributes to Orforglipron evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Orforglipron and Apolipoprotein B change
Intervention: OrforglipronOutcome: Apolipoprotein B change
1 results
All studies on Orforglipron and Apolipoprotein C3 change
Intervention: OrforglipronOutcome: Apolipoprotein C3 change
1 results
All studies on Orforglipron
Intervention: Orforglipron
1 results
All studies measuring Apolipoprotein B change
Outcome: Apolipoprotein B change
1 results
All studies measuring Apolipoprotein C3 change
Outcome: Apolipoprotein C3 change
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Orforglipron improve apolipoprotein b change?
Emerging Evidence
Orforglipron appears to improve Apolipoprotein B change.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Apolipoprotein B change
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Orforglipron improve apolipoprotein c3 change?
Emerging Evidence
Orforglipron appears to improve Apolipoprotein C3 change.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Apolipoprotein C3 change
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Orforglipron improve c-reactive protein?
Emerging Evidence
Orforglipron appears to improve C-reactive protein.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
C-reactive protein
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Orforglipron improve diastolic blood pressure?
Emerging Evidence
Orforglipron appears to improve Diastolic blood pressure.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Diastolic blood pressure
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Weight Loss Methods Improve Insulin Resistance in Type 2 DiabetesHealthy Nordic Diet Improves Liver Fat in Type 2 DiabetesExercise therapy reduces blood pressure in multimorbidity.Mediterranean ketogenic eating matched VLCKD for weight loss over 3 monthsMobile health support improves blood glucose levels in type 2 diabetes
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.